Nasal spray may offer fast hives relief without needles
NCT ID NCT05496465
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single dose of a nasal spray called ARS-1 (intranasal epinephrine) in 21 adults who get frequent hives and itching. The goal was to see if the spray works faster and better than a placebo at reducing itch and hive scores during flare-ups. Participants were monitored for safety and symptom improvement over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, 45236, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app ease the misery of eczema, psoriasis, and hives?
- AI tool aims to cut allergy misdiagnosis in primary care
- New tablet shows promise for chronic hives in small study
- New gel promises Ultra-Fast itch relief in seconds
- Ear seeds and allergy pills: a new combo for hives?
- Smartphone AI could help doctors monitor skin disease remotely